

Clinical Approach to Infection in the Compromised Host

Third Edition

Clinical Approach to Infection in the Compromised Host

Third Edition

Edited by

ROBERT H. RUBIN, M.D.

*Chief of Transplantation Infectious Disease
Massachusetts General Hospital
Boston, Massachusetts
and Director of the Center for Experimental Pharmacology and Therapeutics
Harvard University–Massachusetts Institute of Technology
Division of Health Sciences and Technology
Cambridge, Massachusetts*

and

LOWELL S. YOUNG, M.D.

*Director of Kuzell Institute for Arthritis and Infectious Diseases
Chief of Division of Infectious Diseases
Pacific California Medical Center
San Francisco, California*

With a Foreword by

PAUL S. RUSSELL, M.D.

*John Homans Professor of Surgery
Harvard Medical School
and Visiting Surgeon
Massachusetts General Hospital
Boston, Massachusetts*

**PLENUM MEDICAL BOOK COMPANY
NEW YORK AND LONDON**

Library of Congress Cataloging in Publication Data

Clinical approach to infection in the compromised host / edited by Robert H. Rubin and Lowell S. Young; with a foreword by Paul S. Russell.—3rd ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-306-44617-0

1. Communicable diseases. 2. Opportunistic infections. 3. Immunological deficiency syndromes—Complications. I. Rubin, Robert H., DATE. II. Young, Lowell S.

[DNLM: 1. Immunologic Deficiency Syndromes—complications. 2. Immunocompromised Host—immunology. 3. Acquired Immunodeficiency Syndrome—immunology. WD 308 C6408 1994]

RC112.C59 1994

616.9'0479—dc20

DNLM/DLC

94-5811

for Library of Congress

© 1994, 1988, 1981 Plenum Publishing Corporation

233 Spring Street, New York, N.Y. 10013

Plenum Medical Book Company is an imprint of Plenum Publishing Corporation

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Contributors

Neil M. Ampel • Department of Medicine, Section of Infectious Diseases, Veterans Administration Medical Center, and University of Arizona Health Sciences Center, Tucson, Arizona 85724

Thomas Barber • Boston University School of Medicine; The Thorndike Memorial Laboratory; and Department of Medicine, Boston City Hospital, Boston, Massachusetts 02118

Raleigh A. Bowden • Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104

Stephen J. Chanock • Pediatric Branch, Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892

John C. Christenson • Department of Pediatrics, Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah 84132

A. Benedict Cosimi • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114

Clyde S. Crumpacker • Division of Infectious Diseases, Beth Israel Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114

Jules L. Dienstag • Gastrointestinal Unit, Medical Services, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114

Jay Alan Fishman • Infectious Disease Unit, Medical Service and Transplantation Unit, Surgical Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

Michael S. Gottlieb • Department of Medicine, University of California, Los Angeles, California 90024

Reginald Greene • Chest Division, Radiology Service, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114

Roy M. Gulick • Division of Infectious Diseases, Department of Medicine, New York University Medical Center, New York, New York 10016

Harry R. Hill • Departments of Pediatrics and Pathology, Division of Clinical Immunology and Allergy, University of Utah School of Medicine, Salt Lake City, Utah 84132

Martin S. Hirsch • Infectious Disease Unit, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114

Richard Allen Johnson • Department of Dermatology, Massachusetts General Hospital, New England Deaconess Hospital, and Harvard Medical School, Boston, Massachusetts 02114

William N. Katkov • Division of Gastroenterology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024

Elaine T. Kaye • Department of Dermatology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114

Joel D. Meyers† • Formerly of Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104

Donald G. Payan • Division of Infectious Diseases, University of California, San Francisco, California 94143

Philip A. Pizzo • Pediatric Branch, Infectious Diseases Section, National Cancer Institute, Bethesda, Maryland 20892

Robert H. Rubin • Infectious Disease and Transplantation Units, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114; and the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts 02142

W. Michael Scheld • Departments of Internal Medicine (Infectious Diseases) and Neurosurgery, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

Robert T. Schooley • Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262

Arthur J. Sober • Dermatology Service, Massachusetts General Hospital, and Department of Dermatology, Harvard Medical School, Boston, Massachusetts 02114

Alan M. Sugar • Boston University School of Medicine; The Thorndike Memorial Laboratory; Department of Medicine, Boston City Hospital; and Evans Memorial Department of Clinical Research and Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118

Allan R. Tunkel • Department of Internal Medicine (Infectious Diseases), Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129

Jos W. M. van der Meer • Division of General Internal Medicine, University Hospital St. Radboud, 6500 HB Nijmegen, The Netherlands

James C. Wade • Section of Infectious Diseases and Microbiology, Division of Oncology and Infectious Diseases, University of Maryland Cancer Center, University

of Maryland School of Medicine, Baltimore, Maryland 21201

L. Joseph Wheat • Departments of Medicine and Pathology, Indiana University School of Medicine; Richard L. Roudebush Veterans Administration Hospital; and Wishard Memorial Hospital, Indianapolis, Indiana 46202

Edward J. Wing • Montefiore University Hospital, and Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

John S. Wolfson† • Formerly of Infectious Disease Unit, Medical Services, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114

Lowell S. Young • Kuzell Institute for Arthritis and Infectious Disease, Division of Infectious Diseases, Pacific Presbyterian Medical Center, San Francisco, California 94115

†Deceased

Foreword to the Third Edition

Not long ago it was a common opinion that the subject of controlling infections in the “compromised host” was a rather obscure corner of medicine occupied only with bizarre examples of rarities that the ordinary clinician could probably ignore without much damage to his working knowledge or to the safety of his patients. Recent experience has piled up in an overwhelming way on the other side of this question. It is now, of course, abundantly clear that such patients, far from being scarce, are likely to become increasingly central to the responsibility of medicine as a whole. Patients in this class offer the utmost challenge to those responsible for their care and are fascinating subjects of study and strong goads toward further learning. The compromised host lies open, as a form of exposed, all-purpose culture plate. Not only do such patients admit many kinds of ambient organisms with startling ease, but they usually do so in relative silence. Thus, in their early stages, only muted signals of trouble may be detectable by even the most observant physician. If these weren’t enough, the picture is further confounded by the fact that the ability of such patients to throw off extraneous pathogens is, by definition, compromised. The nature of the compromise enlists still more variables and complexities, making the analysis of the circumstances presented by an individual patient all the more demanding. What is demanded most is an expert in situations like this, and the collection of expert views in this volume is the kind of help that the nonexpert sorely needs. What the generalist soon finds in working with an expert in this field is that the special strength of his opinion can be carried over to the management of ordinary patients with common infections. The presence of such an expert gives one a comfortable feeling that is probably akin to what a coach might feel if he could summon a pinch hitter to the plate who can hit home runs with two bats in his hands instead of one.

This third edition of Rubin and Young’s widely read volume fully reflects the broad range of the subject at hand, giving special, and entirely justified, emphasis to the most prevalent immunocompromising situation of all, the individual infected with the human immunodeficiency virus. On reflection, this class of infections offers a particular curiosity because it is the primary infection

itself that brings on immunological compromise, thereby generating a kind of “open season” for further invasion by still other organisms, and a dazzling array of organisms has to be considered. Intentionally immunosuppressed patients offer another class in which infections represent a secondary result from a primary, well-defined factor that is especially frustrating since it is usually quite resistant to change. Thus, the AIDS patient and the heart transplant recipient have several features in common, including a significant, and still incompletely explained, risk of developing malignant neoplasms.

In the early days of transplantation the doses of immunosuppressive agents that would be required for optimal control of rejection reactions were unknown. Not surprisingly, we were quite ill prepared to deal with the infectious complications of their use. As the doses of these agents tended to be larger than they are now, devastating infections were all too common. In retrospect, this situation proved to offer remarkable opportunities for the pioneering infectious disease specialists who entered the field at that time. The transplant recipient usually begins his period of immunocompromise at a time that can be anticipated in advance. This gives the expert in immunosuppression for transplantation valuable insights in handling patients already suffering from advanced immunocompromise from other causes. Thus, handling the problems presented by patients who have suffered immunocompromise, either in the course of their underlying illnesses or because of intentional immunosuppression, falls naturally into the same book and into the same growing medical specialty.

Current approaches to the evaluation of infections in compromised hosts and the substantial advances in their treatment are impressive. They are much superior to the best available only a few years ago. Nevertheless, one has the feeling that our present circumstances must represent a fairly early stage along the visible road to further improvements. The limited place now occupied by isolation techniques and the use of chronic antibiotic treatment to suppress, but not eliminate, certain types of infections will be interesting to watch in the future. These modalities may be used even less than they are today. Perhaps the biggest question for the future, how-

ever, will be the place of new approaches to heightening or restoring the intrinsic defenses of the host. With the identification and production of a growing number of cytokines, and greatly expanded information about the complex world of intercellular signaling, many new opportunities are unfolding. One already sees the value of this knowledge in situations where leukopenias are rapidly reversed by treatments with granulocyte-stimulating factors. Accordingly, it now seems likely that a valuable part of the management of compromised patients will soon include the individualized restoration of immune competence in addition to direct assaults on the offending organisms from without.

I look for this authoritative and up-to-date account of the management of infections in compromised hosts to be as thoroughly useful as were its predecessors. I must express the hope, however, that the subject will continue to advance in such a way that yet another volume will be called for by acclamation.

Paul S. Russell, M.D.
Department of Surgery
Massachusetts General Hospital
and Harvard Medical School
Boston, Massachusetts

Preface

In the spring of 1977, at the annual Epidemic Intelligence Service Conference of the Centers for Disease Control, two friends from medical school days, one now in California and one still in Boston, met and began to discuss their current clinical and research interests. By happy coincidence, we had both become immersed in what was then deemed a highly esoteric, ivory tower series of problems—those of the immunocompromised host. We belonged to a small community of clinical investigators who were part infectious disease clinicians, part microbiologists, part clinical immunologists, and part white cell biologists. We regarded the infections that were being seen in the transplant patient, the cancer patient, and the child with a congenital immunodeficiency disorder as both important clinical problems and as an opportunity for studying host–pathogen interactions.

Already there was a burgeoning literature from this small community of scholars, and there were beginning hints that because of strides being made in transplantation, cancer chemotherapy, and the use of immunosuppressive drugs for the treatment of autoimmune disease, the infectious disease problems of these patients would be of increasing interest and importance to the general medical community. We felt that a critical review of these subjects, the combination of a practical management strategy with the most up-to-date scientific information, and a delineation of the areas most needing further study, would help in advancing this area of clinical medicine. Thus, the first edition of this book was born.

In the nearly two decades that have elapsed since our first conversation and this, the third edition of *Clinical Approach to Infection in the Compromised Host*, this field has burgeoned in remarkable fashion. The infectious disease problems of the immunocompromised host have indeed become the concern of all practitioners of medicine, of as much concern to the primary care physician as the tertiary care specialist. The population of patients at risk has grown logarithmically because of the tragedy of AIDS and the remarkable success being achieved with modern immunosuppressive therapy in so many areas of medicine. Gratifyingly, there has been an accompanying explosion of information on the science and practice of caring for the infectious disease problems

of these patients. Despite the medical conferences, new journals, newsletters, cassettes, videotapes, and other multimedia attempts to convey the necessary information to the expanding group of physicians who need such knowledge, we continue to believe that there is a compelling need for the clinician to have access in the dead of night or the heat of day to well-written, sage advice from veterans of battles similar to those they are now undertaking. This book continues to attempt to fulfill these needs. We have previously stated that the best way to learn is to sit at the feet of a master for several years—like Mark Hopkins and the Log. It is our hope that we have been able to bring together a group of Mark Hopkinses, all veterans of these battles and distinguished contributors to the field, with this book serving as a Log for all those with a need to know. All credit for achieving these objectives is owed to our contributors. We accept responsibility for any inadequacies.

As we have been privileged to contribute and to edit all three editions of this book, it is of interest to chronicle the changes that have occurred. At the time the first edition went to press, we had never heard of AIDS; in the current edition there are five separate chapters dealing with this subject, and issues related to HIV infection and AIDS can be found in virtually every other chapter as well. In the first edition, the only organ being transplanted was the kidney; now we discuss the liver, the heart, and the lungs as well, and begin to touch on the pancreas and the small bowel. Our understanding of host–parasite interactions and principles of patient management has likewise grown extensively. It is little wonder that this edition is at least 75% larger than the original volume, despite intensive efforts at editing. We are excited that the expansion in this field has necessitated and justified such an increase in material.

As we peruse this edition, we are also reminded that as in any dynamic field of medicine and science we stand on the shoulders of those who have gone before. These include our teachers, our patients, and our colleagues. Unfortunately, much of what we have learned has come from the study of patients who, despite the best efforts that could be made, have succumbed to their infections. Memories of them and their courage in the face of ex-

treme adversity continue to inspire us, and this book is in part dedicated to them. It is also dedicated to two friends and colleagues, whose contributions to this book, to medicine, and to our community continue, but who have been taken from us prematurely at the peaks of their careers. This book honors the memories of Dr. Joel

Meyers and Dr. John Wolfson—gentlemen, scholars, and compassionate physicians; we are all poorer for their absence, and are grateful for the time we had with them.

Robert H. Rubin
Lowell S. Young

Boston and San Francisco

Preface to the First Edition

The science and practice of infectious disease cut across all medical disciplines, from medicine to surgery, and from cardiology to neurology. Because of the diverse nature of infection and the clinical settings in which it occurs, the acquisition of the skills needed to become expert in clinical infectious diseases has usually required a lengthy apprenticeship. As one of us has noted, "The practice of infectious disease is akin to many primitive arts, being handed down by oral traditions from generation to generation. The best way to learn is to sit at the feet of a master for several years, asking, observing, and studying—the medical equivalent of Mark Hopkins and the Log."

However, increasingly it has become apparent that a more efficient means of communicating the art and science of clinical infectious disease to the general medical community is necessary. The infections themselves, the potential therapeutic modalities, the clinical settings in which they occur, and the occurrence of such infections far away from the academic medical center—all these have put a new emphasis on disseminating the most up-to-date information available to diagnose and treat clinical infection. This is particularly true when one considers the gamut of infections that afflict the patient with a defect in host defense. Those of us with a particular interest in this area of medicine and infectious diseases are painfully aware of the special nature of these patients and their problems and the rather extended apprenticeship we have served in learning to deal with these problems. We have been impressed that although great strides had been taken in general infectious disease in moving beyond the Log and the oral tradition, in this area of infectious disease such efforts are just beginning. Thus, the idea for this book was conceived to attempt to meld the scientific advances in this area with the experience that we had had in dealing with such patients to construct a useful, practical guide to the problem of infection in

the compromised host. We wanted to share the fruits of our apprenticeship with the rest of the medical community who increasingly are being called upon to deal with these clinical problems.

The next step was to find out whether a publisher would be interested. Ms. Hilary Evans of Plenum was quickly recruited to the effort. She has been a bulwark of strength and encouragement during the lengthy gestation period. Finally, there comes the recruitment of the other contributors. Perhaps the most pleasant surprise in this whole experience was the enthusiasm with which our contributors brought their expertise to the endeavor—all of us agreeing that a need existed for a practical guide to patient management in the immunosuppressed host that was based upon firm scientific data whenever this was available and on the art and judgment of medicine when such data was unavailable. With admiration and gratitude we thank our contributors, who have taught us so much in the preparation of this book.

Finally, it is fitting that we express our gratitude to three different groups of individuals who have made this book possible—our teachers, Mort Swartz, Louis Weinstein, Alex Langmuir, Don Armstrong, and Don Louria, who have served as our models in their ability to blend the sciences of microbiology, immunology, and epidemiology with the art of clinical medicine; our families, who have supported us in this effort and whose time has been stolen to prepare this work; and, perhaps most of all, our patients, the immunocompromised patients with life-threatening infections who continue to teach us and inspire us with their courage and faith as we painfully learn how best to deal with infection in the compromised host.

Robert H. Rubin
Lowell S. Young

Boston and Los Angeles

Contents

1	Introduction	1
	LOWELL S. YOUNG and ROBERT H. RUBIN	
2	Epidemiology and Prevention of Infection in the Compromised Host	5
	JAMES C. WADE	
1.	Infection as It Relates to Defects in Host Defense	5
1.1.	Granulocytopenia	5
1.2.	Cellular Immune Dysfunction	6
1.3.	Humoral Immune Dysfunction	7
1.4.	Obstruction of Natural Body Passages	7
1.5.	Iatrogenic Procedures	7
2.	Origin of Infecting Organisms	7
2.1.	Shifts in Microbial Flora	8
2.2.	Sources of Acquisition of Exogenous Organisms	10
3.	Infection Prevention: Effective but Complex Techniques	11
3.1.	Reverse Isolation in Laminar Airflow Rooms and Other Forms of Complete Barrier Isolation	11
3.2.	Microbial Suppression with Oral Nonabsorbable Antibiotics	12
3.3.	Combined Use of Laminar Airflow Room or Similar Isolation plus Microbial Suppression with Oral Nonabsorbable Antibiotics	12
3.4.	Need for Simplified and Effective Techniques of Infection Prevention	13
3.5.	Prophylactic Granulocyte Transfusions	13
4.	Ineffective Techniques of Infection Prevention	13
4.1.	Standard Reverse Isolation	13
4.2.	Reduction of the Acquisition of Organisms	13
5.	Suppression of Potential Pathogens	14
5.1.	Granulocytopenia	14
5.2.	Disadvantages of Selective Microbial Modulation	15
5.3.	Fungal Prophylaxis	17
5.4.	Oral Nonabsorbable Antifungal Agents	17
5.5.	Systemic Imidazole and Triazole Antifungal Agents	17
5.6.	Amphotericin B Nose Spray	19
5.7.	Skin	19
5.8.	Dental Hygiene	20
6.	Cellular Immune Dysfunction	20
6.1.	Tuberculosis	20
6.2.	<i>Pneumocystis carinii</i> Pneumonia	20
6.3.	Varicella–Zoster Virus	20
6.4.	Herpes Simplex Virus	22
6.5.	Cytomegalovirus	23
7.	Humoral Immune Dysfunction	24
7.1.	Pneumococcal Vaccine	24

7.2. Relief of Obstruction.....	25
7.3. Care in the Breaching of Body Barriers	25
7.4. Staff Education	25
7.5. Patient Education.....	25
References	25

3 Defects in Host Defense Mechanisms 33

JOS W. M. VAN DER MEER

1. Colonization	33
2. First Line of Defense.....	33
2.1. Skin	33
2.2. Mucosa.....	33
3. Second Line of Defense.....	34
3.1. Humoral Defense Mechanisms	34
3.2. Cellular Defense Mechanisms	40
4. Factors That Influence the Quality of Host Defense	46
4.1. Genetic Control of Host Defense against Infection.....	46
4.2. Nutritional Status.....	46
4.3. Age and Host Defense	47
4.4. Body Temperature and Host Defense.....	47
4.5. Stress and Host Defense	47
5. Diseases That Affect Host Defense.....	47
5.1. Leukemia and Lymphoma	48
5.2. Splenectomy	48
5.3. Sickle Cell Anemia	49
5.4. Diabetes Mellitus.....	49
5.5. Chronic Renal Failure	49
5.6. Alcoholism and Hepatic Cirrhosis	50
5.7. Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Felty's Syndrome	50
5.8. Infections	51
6. Immunosuppressive Drugs.....	52
6.1. Glucocorticosteroids	52
6.2. Other Immunosuppressive Agents	52
7. Plasmapheresis	53
8. Radiation.....	53
9. Attempts to Strengthen Host Defense.....	54
References	55

4 Fever and Septicemia 67

LOWELL S. YOUNG

1. Introduction	67
2. Criteria for Fever, Fever of Undetermined Origin, and Septicemia	67
3. Pathogenesis of Fever	68
4. Syndrome-Oriented Approach to Fever and Suspected Infection: Differential Diagnosis	70
5. Some Emerging Pathogens in the Immunocompromised Host	75
6. Clinical Approach to Fever: History and Physical Examination.....	75
7. Interaction between the Clinician and the Microbiology Laboratory	78
8. Specific Laboratory Studies.....	78
9. Diagnosis of Infection: Antibody Measurements and Skin Tests	80
10. Noninvasive Diagnostic Procedures	80
11. Invasive Diagnostic Procedures.....	81
12. Diagnostic Tests of Limited Usefulness	81

13. Persistent or Recurrent Fever in the Patient with Negative Cultures: Diagnostic Considerations	82
14. Findings Suggestive of Microbial Infection Rather Than Fever Secondary to Underlying Disease	85
15. Initial or Empiric Antimicrobial Therapy: Indications for Treatment	85
16. Relationship of Antimicrobial Therapy and Underlying Disease to Outcome of Infection	86
17. Factors That Underlie Recommendation of Initial or Empiric Antimicrobial Therapy Regimens	86
18. Antimicrobial Agents	90
18.1. Aminoglycosides	90
18.2. Antipseudomonal Penicillins	91
18.3. Cephalosporins	91
18.4. Antistaphylococcal Semisynthetic Penicillins	92
19. Is Specific Antistaphylococcal Therapy Necessary?	92
20. Alteration of Empiric Therapy after Documentation of Bacterial Infection	93
21. Role of Other Antibacterial Agents in Therapy	93
22. Therapeutic Drug Monitoring	94
23. Management of Catheter-Associated Infection	95
24. Should Fever Be Suppressed?	96
25. Therapy of Underlying Disease during Documented Infection	96
26. Duration of Antimicrobial Therapy in Documented Infection	96
27. Undocumented Infection and the Decision to Continue or Withhold Antimicrobial Agents	96
28. Recommendations for Continuing or Discontinuing Antimicrobial Therapy and Initiating Empiric Antifungal Therapy	98
29. Adjunctive Use of Corticosteroids, Antibodies, and Other Therapeutic Modalities in the Sepsis Syndrome	99
References	100

5 Dermatologic Manifestations of Infection in the Compromised Host 105

**ELAINE T. KAYE, RICHARD ALLEN JOHNSON,
JOHN S. WOLFSON, AND ARTHUR J. SOBER**

1. Introduction	105
2. Skin as a Barrier to Infection	105
3. Types of Skin Infection	106
3.1. Primary Skin Infection with Common Pathogens	107
3.2. Unusually Widespread Cutaneous Infection	107
3.3. Opportunistic Primary Cutaneous Infection	109
3.4. Systemic Infection Metastatic to Cutaneous and Subcutaneous Sites	110
4. Dermatologic Lesions Associated with Acquired Immunodeficiency Syndrome	114
5. Diagnostic Aspects of Skin Infections in the Compromised Patient	114
References	115

6 Clinical Approach to the Compromised Host with Fever and Pulmonary Infiltrates 121

ROBERT H. RUBIN AND REGINALD GREEN

1. The Febrile Pneumonitis Syndrome and Its Importance	121
2. Overview of Infectious Causes of the Febrile Pneumonitis Syndrome in the Immunocompromised Host	122
2.1. Factors That Determine the Risk of Pulmonary Infection	123

2.2. Pathology of Pulmonary Infections in the Immunocompromised Host	129
2.3. Clinical Clues to the Diagnosis of Pulmonary Infection	131
3. Overview of Noninfectious Causes of the Febrile Pneumonitis Syndrome	132
3.1. Radiation Pneumonitis	132
3.2. Drug-Induced Pneumonitis	134
3.3. Neoplastic Pulmonary Invasion	137
3.4. Other Noninfectious Causes of the Febrile Pneumonitis Syndrome	137
4. Radiologic Clues to the Diagnosis of the Febrile Pneumonitis Syndrome	138
4.1. Correlation of Radiologic Findings, Rate of Progression, and Clinical Signs	140
4.2. Radiologic Aspects of Thoracic Disease in Acquired Immunodeficiency Syndrome Patients	146
5. Specific Diagnosis	149
5.1. Immunologic Techniques for Specific Diagnosis	149
5.2. Sputum Examination	150
5.3. Invasive Diagnostic Techniques	151
6. Superinfection	154
References	154

7 Central Nervous System Infection in the Immunocompromised Host 163

ALLAN R. TUNKEL AND W. MICHAEL SCHELD

1. Introduction	163
2. Viral Infections	163
2.1. Human Immunodeficiency Virus-Type 1	163
2.2. Herpesviruses	167
2.3. Progressive Multifocal Leukoencephalopathy	170
3. Bacterial Infections	172
3.1. Meningitis	172
3.2. Brain Abscess	179
3.3. Tuberculosis	182
4. Fungal Infections	186
4.1. Meningitis	186
4.2. Brain Abscess	190
5. Protozoal Infections	193
5.1. Toxoplasmosis	193
5.2. Strongyloidiasis	196
References	197

8 Fungal Infections in the Immunocompromised Host 211

L. JOSEPH WHEAT

1. Introduction	211
2. Fungal Infections in Granulocytopenia	211
3. Fungal Infections in Organ Transplantation	212
4. Fungal Infections in Acquired Immunodeficiency Syndrome	212
5. Candidiasis	213
5.1. Epidemiology	213
5.2. Clinical Manifestations	213
5.3. Diagnosis	214
5.4. Treatment	214
5.5. Prevention	215

6. Aspergillosis	217
6.1. Epidemiology	217
6.2. Clinical Manifestations	218
6.3. Diagnosis	219
6.4. Treatment	220
6.5. Prevention	221
7. Mucormycosis	222
7.1. Epidemiology	222
7.2. Clinical Manifestations	222
7.3. Diagnosis	222
7.4. Treatment	222
8. Cryptococcosis	223
8.1. Epidemiology and Pathogenesis	223
8.2. Clinical Manifestations	223
8.3. Diagnosis	223
8.4. Treatment	224
9. Histoplasmosis	225
9.1. Epidemiology	225
9.2. Clinical Manifestations	226
9.3. Diagnosis	226
9.4. Treatment	226
10. Coccidioidomycosis	227
10.1. Epidemiology	227
10.2. Clinical Manifestations	228
10.3. Diagnosis	228
10.4. Treatment	228
11. Unusual Fungal Pathogens	229
12. Antifungal Agents	229
12.1. Amphotericin B	229
12.2. Liposomal and Lipid Complexes of Amphotericin B	230
12.3. 5-Flucytosine	230
12.4. Ketoconazole	230
12.5. Fluconazole	230
12.6. Itraconazole	231
References	232

9 Mycobacteriosis and Nocardiosis in the Immunocompromised Host 239

THOMAS BARBER AND ALAN M. SUGAR

1. Introduction	239
2. Mycobacteria	240
2.1. Microbiology	240
2.2. Diagnosis	240
2.3. Epidemiology and Pathogenesis	242
2.4. Mycobacterial Disease and Malignancy	247
2.5. Immunosuppressive Therapy	248
2.6. BCG Vaccination and Immunotherapy	249
2.7. Nosocomial Mycobacterial Disease	250
2.8. End-Stage Renal Disease	251
2.9. Organ Transplantation	251
2.10. Other Conditions Associated with Mycobacteriosis	252
2.11. Human Immunodeficiency Virus Infection	253
2.12. Prophylaxis and Treatment of Mycobacterial Diseases	256
3. Nocardiae	258
3.1. Organisms	259
3.2. Epidemiology	259

3.3. Pathogenesis	259
3.4. Clinical Presentation	260
3.5. Diagnosis	261
3.6. Therapy	263
4. Conclusions	265
References	265

10 *Pneumocystis carinii* and Parasitic Infections in the Immunocompromised Host..... 275

JAY ALAN FISHMAN

1. Introduction	275
1.1. Parasite Factors: Development and Distributions	275
1.2. Host–Parasite Interactions and Mechanisms of Immune Evasion	276
1.3. Missing Infections in Acquired Immunodeficiency Syndrome	277
2. <i>Pneumocystis carinii</i>	277
2.1. The Organism: Taxonomy and Life Cycle	278
2.2. Epidemiology	280
2.3. Acquired Immunodeficiency Syndrome	281
2.4. Clinical Pneumocystosis	282
2.5. Radiology of <i>Pneumocystis carinii</i> Pneumonia	285
2.6. Laboratory Evaluation	287
2.7. Histopathologic Diagnosis	288
2.8. Therapy of <i>Pneumocystis carinii</i> Infections	291
2.9. Prevention of <i>Pneumocystis carinii</i> Pneumonia in the Susceptible Host	295
3. <i>Toxoplasma gondii</i>	297
3.1. The Organism	297
3.2. The Patient	298
3.3. Diagnosis	301
3.4. Therapy of <i>Toxoplasma gondii</i> Infection	304
4. <i>Cryptosporidium</i> Species	306
4.1. The Organism	306
4.2. Epidemiology	306
4.3. Diagnosis	307
4.4. The Patient	308
4.5. Therapy of <i>Cryptosporidium</i>	308
5. <i>Isospora belli</i>	309
5.1. The Organism: Life Cycle and Epidemiology	309
5.2. The Patient	309
5.3. Histopathology and Diagnosis	309
5.4. Therapy	309
6. Microsporidia	310
6.1. The Organism	310
6.2. The Patient	310
6.3. Diagnosis and Therapy	310
7. <i>Strongyloides stercoralis</i>	311
7.1. The Organism	312
7.2. Epidemiology	312
7.3. Pathogenesis	313
7.4. The Patient	313
7.5. Disseminated Strongyloidiasis: “Hyperinfection Syndrome”	314
7.6. Diagnosis	314
7.7. Therapy	315
8. <i>Entamoeba histolytica</i>	316
8.1. The Organisms	316
8.2. Life Cycle	316

8.3. Epidemiology.....	316
8.4. Immunology.....	317
8.5. Pathogenesis	317
8.6. The Patient.....	317
8.7. Diagnosis	318
8.8. Therapy	319
9. Primary Amebic Meningoencephalitis	320
9.1. The Organism	320
9.2. Epidemiology.....	320
9.3. Pathogenesis	320
9.4. The Patient and Diagnosis	320
9.5. Therapy	320
10. Leishmaniasis	321
10.1. The Organism	321
10.2. Epidemiology.....	321
10.3. Pathogenesis	321
10.4. Immunology.....	322
10.5. The Patient: Clinical Manifestations	322
10.6. Diagnosis and Therapy	322
11. Other Parasitic Diseases of the Immunocompromised Host	323
11.1. <i>Giardia lamblia</i>	323
11.2. Malaria.....	323
11.3. Babesiosis	324
11.4. American Trypanosomiasis (Chagas' Disease)	324
11.5. African Trypanosomiasis.....	325
11.6. <i>Cyclospora</i>	325
References	325

11 Legionellosis in the Compromised Host..... 335

NEIL M. AMPEL and EDWARD J. WING

1. Introduction	335
2. Microbiology	335
2.1. Classification	335
2.2. Morphology	336
2.3. Cultural and Biochemical Characteristics	336
3. Pathology, Pathogenesis, and Immunology	336
3.1. Pathology and Pathogenesis	336
3.2. Immunology.....	337
4. Epidemiology	338
4.1. General Considerations	338
4.2. Ecology	338
4.3. Nosocomial Legionellosis.....	338
5. Clinical Manifestations	340
5.1. Symptoms and Signs.....	340
5.2. Laboratory Findings	341
5.3. Radiographic Manifestations.....	341
6. Diagnosis	342
6.1. Differential Diagnosis	342
6.2. Dual Infection	342
6.3. Specific Diagnosis.....	342
6.4. Diagnostic Approach.....	345
7. Treatment	345
7.1. Retrospective Studies	345
7.2. Animal Trials.....	346
7.3. <i>In Vitro</i> Assays	346
7.4. Recommendations	346
7.5. Course	347
References	347

12 Viral Hepatitis in the Compromised Host..... 355

JULES L. DIENSTAG and WILLIAM N. KATKOV

1. Introduction	355
2. Role of Immunologic Mechanisms in the Pathogenesis of Viral Hepatitis	355
2.1. Hepatitis B.....	355
2.2. Hepatitis C.....	357
3. Viral Hepatitis in the Immunocompromised Host	357
3.1. Hemodialyzed Patients with Chronic Renal Failure	358
3.2. Hepatitis in Recipients of Organ Transplants	360
3.3. Hepatitis in Oncology Patients	367
3.4. Hepatitis in Patients with AIDS	369
4. Prevention.....	370
5. Summary.....	372
References	372

13 Herpes Group Virus Infections in the Compromised Host 379

MARTIN S. HIRSCH

1. Introduction	379
2. Herpes Simplex Virus	379
2.1. Clinical Epidemiology and Patterns of Infection.....	379
2.2. Pathogenesis	381
2.3. Diagnosis and Therapy	382
3. Varicella–Zoster Virus.....	383
3.1. Clinical Epidemiology and Patterns of Infection.....	384
3.2. Pathogenesis	385
3.3. Diagnosis and Therapy	386
4. Cytomegalovirus	387
4.1. Clinical Epidemiology and Patterns of Infection.....	387
4.2. Pathogenesis	388
4.3. Diagnosis and Therapy	389
5. Epstein–Barr Virus	390
5.1. Clinical Epidemiology and Patterns of Infection.....	390
5.2. Pathogenesis	390
5.3. Diagnosis and Therapy	391
6. Other Human Herpesviruses	392
References	392

14 Morbidity in Compromised Patients Related to Viruses Other Than Herpes Group and Hepatitis Viruses..... 397

ROBERT T. SCHOOLEY

1. Introduction	397
2. DNA Viruses	397
2.1. Adenoviruses	397
2.2. Papovaviruses	399
2.3. Vaccinia	402
3. RNA Viruses	402
3.1. Picornaviruses	402
3.2. Paramyxoviruses	404

3.3. Rotaviruses	405
References	405

15 Pathogenesis and Clinical Manifestations of HIV-1 Infection 411

ROBERT T. SCHOOLEY

1. Primary HIV-1 Infection	411
2. HIV-1-Associated Immunodeficiency	412
3. Neurologic Manifestations of HIV-1 Infection	413
4. Pathogenesis of the Neurologic Complications of HIV-1	413
5. Clinical Manifestations of AIDS Dementia Complex	414
6. Aseptic Meningitis	414
7. Subacute Encephalitis	414
8. Peripheral Neuropathy	415
9. Vacuolar Myelopathy	416
10. Cachexia and Wasting in HIV-1 Infection	416
11. Pathogenesis of HIV-Associated Wasting	416
12. Metabolic Disturbances	416
13. Decreased Caloric Intake in AIDS	416
14. Management of HIV-1-Associated Cachexia	417
References	417

16 Human Immunodeficiency Virus Disease and Its Complications 423

MICHAEL S. GOTTLIEB

1. Introduction	423
2. Symptom Complex: Fever in the Patient with HIV Disease	423
3. Symptom Complex: Fever and Nonproductive Cough	426
4. Symptom Complex: Fever and Productive Cough	428
5. Symptom Complex: Fever and Headache	429
6. Symptom Complex: The Clinical Approach to Diarrhea in HIV Disease	430
6.1. Protozoal Causes of Diarrhea	431
6.2. Viral Causes of Diarrhea	432
6.3. Mycobacterial Causes of Diarrhea	432
6.4. Drug-Induced Diarrhea	433
6.5. Bacterial Causes of Diarrhea	433
6.6. AIDS Enteropathy	433
7. Symptom Complex: Dysphagia and Odynophagia	434
8. Symptom Complex: Pain	435
9. Symptom Complex: Disorders in the Oral Cavity	437
10. Women: Specific HIV Disease Manifestations	437
10.1. <i>Candida</i> Infections	438
10.2. Human Papillomavirus Infections	438
10.3. Herpes Simplex Virus Infections	438
11. Ocular Infections in HIV Disease	439
12. Brain Infections in Advanced HIV Disease	440
13. Dermatologic Aspects of HIV Disease	442
13.1. Viral Infections	442
13.2. Fungal Infections	442
13.3. Scaling Skin Conditions	442
13.4. Itchy Bumps	444
References	444

17 The Mucocutaneous Problems Associated with Human Immunodeficiency Virus Infection	449
RICHARD ALLEN JOHNSON and ROBERT H. RUBIN	
1. Introduction	449
2. Epidemiology and Pathogenesis of HIV Infection	449
3. Clinical Features of HIV Disease	451
3.1. Mucocutaneous Aspects of HIV-Associated Kaposi's Sarcoma	451
3.2. Mucocutaneous Infections of Particular Importance in HIV Disease	453
3.3. Noninfectious Forms of Mucocutaneous Disease of Importance in the HIV-Infected Individual	462
References	463
18 Treatment of Viral Infections in the Human Immunodeficiency Virus-Infected Patient	469
ROY M. GULICK and CLYDE S. CRUMPACKER	
1. Herpes Simplex Virus	469
1.1. Acyclovir Treatment of Herpes Simplex Infection	470
1.2. Acyclovir Resistance of Herpes Simplex Virus	471
1.3. Vidarabine Treatment of Herpes Simplex Infection	471
1.4. Foscarnet Treatment of Herpes Simplex Infection	471
1.5. Trifluorothymidine Treatment of Herpes Simplex Infection	472
2. Cytomegalovirus Infection	472
2.1. Treatment of CMV Retinitis	473
2.2. Treatment of Gastrointestinal Tract CMV Infection	474
2.3. Treatment and Prevention of CMV Pneumonia	474
2.4. Treatment of CMV Infection of the Nervous System	475
2.5. Resistance of CMV to Ganciclovir	476
2.6. Alternative Therapies to Ganciclovir	476
3. Varicella-Zoster Virus	477
3.1. Therapy of VZV Infection with Acyclovir	478
3.2. Acyclovir Resistance of VZV	478
3.3. Ganciclovir Therapy of VZV Infection	478
3.4. BV-araU Therapy of VZV Infection	479
3.5. Varicella-Zoster Immune Globulin Therapy	479
4. Human Immunodeficiency Virus	479
5. Parvovirus B19	481
6. Respiratory Syncytial Virus	483
6.1. Therapy of RSV Infection	484
6.2. Ribavirin Therapy of RSV Infection	484
7. Treatment of Hepatitis B and Hepatitis C Infection	484
References	486
19 Infectious Complications in Children with Cancer and Children with Human Immunodeficiency Virus Infection	491
STEPHEN J. CHANOCK and PHILIP A. PIZZO	
1. Introduction	491
2. Background	492

2.1. Cancer	492
2.2. HIV	493
3. Importance of Other Infections in the Pathogenesis of Cancer and HIV Infection	495
3.1. Interface between Cancer and Infection	495
3.2. Interface between HIV and Other Infections	496
4. Perturbations of Host Defense That Contribute to Infection	496
5. Fever in Cancer and HIV	497
6. Diagnostic Evaluation of the Febrile Child	499
7. Bacterial Infections	499
8. Viral Infections	505
8.1. Cytomegalovirus	505
8.2. Herpes Simplex	505
8.3. Varicella-Zoster	506
8.4. Respiratory Viruses	506
9. Fungi	507
10. Protozoa	508
11. Special Considerations in the Presentation of Pulmonary Disease	509
12. Catheter-Associated Infections in Children with Cancer and HIV	510
13. Management of Other Types of Foreign Bodies	514
14. Use of Cytokines in Supportive Care	514
15. The Role of Surgery in the Care of the Immunocompromised Child	515
16. Conclusion	516
References	516

20 Infections Complicating Congenital Immunodeficiency Syndromes

JOHN C. CHRISTENSON and HARRY R. HILL

1. Introduction	521
2. Aim of Therapy in Congenital Immunodeficiency Diseases	523
2.1. Treatment of Life-Threatening Infections	523
2.2. Minimizing the Effects of Less Severe Acute Infections	527
2.3. Prevention of Chronic Infections and Their Sequelae	529
3. Specific Infections in Immunodeficiency Syndromes	532
3.1. Combined B- and T-Cell Defects	532
3.2. Congenital Pure T-Cell Immunodeficiencies	535
3.3. B-Cell Immunodeficiency	536
3.4. Complement Component Deficiencies	537
3.5. Phagocyte Abnormalities	539
References	543

21 Management of Infections in Leukemia and Lymphoma

LOWELL S. YOUNG

1. Introduction	551
2. Host Defenses against Infection in Leukemias and Lymphomas	551
3. The Role of Infection in Mortality from Leukemia and Lymphoma	554
4. Problems with the Interpretation of Fever and Infection Incidence Data in Neutropenic States	556
5. Causes of Fever in Leukemia and Lymphoma	556
6. Site of Involvement and the Nature of the Microbial Pathogen(s)	559
7. Synthesis	564
8. Summary of Recommended Therapeutic Strategies	566
8.1. Different Approaches to Leukemia and Lymphoma	566

8.2. Environmental Considerations	566
8.3. Prophylactic Antibiotics	568
8.4. Systemic Antimicrobial Agents	569
9. Approach to the Splenectomized Patient	570
10. Neutrophil Transfusions in the Treatment and Prophylaxis of Infection	571
11. Immunoprophylaxis and Immunotherapy of Infection	572
11.1. Childhood and Adult Immunizations	572
11.2. Passive Antibody	573
11.3. Influenza Immunization	573
11.4. Pneumococcal Immunization	573
References	575

22 Evaluation and Management of Patients with Collagen Vascular Disease 581

DONALD G. PAYAN

1. Introduction	581
2. Novel Features of Host–Microorganism Interactions in CVD	581
3. Morbidity and Mortality Caused by Infections in Patients with CVD	583
4. Host Abnormalities as Potential Contributing Factors to Infections in Patients with CVD	585
5. Role of Immunosuppressive Therapy in Predisposing Patients with CVD to Infections	587
6. Spectrum of Infection Patients with CVD	588
7. Unique Clinical Features of Infection in Patients with CVD	591
8. Clinical Examples of Infection and Their Management	592
8.1. Altered Mental Status in a Patient with SLE	592
8.2. Pleuritic Chest Pain and Fever in a Patient with SLE	593
8.3. Abdominal Pain in a Patient with SLE	594
8.4. Painful Knee in a Patient with Rheumatoid Arthritis	595
9. Conclusions	596
References	597

23 Infection Complicating Bone Marrow Transplantation 601

RALEIGH A. BOWDEN and JOEL D. MEYERS

1. Introduction	601
2. Recovery of Host Defenses	601
3. Phases of Infection after BMT	602
4. Phase I: Early Infections	603
4.1. Bacteremia	603
4.2. Bacterial Pneumonia	604
4.3. Use of Surveillance Cultures	605
4.4. Hyperalimentation Lines	605
4.5. Antibiotic Treatment	605
4.6. Therapeutic Granulocyte Transfusions	608
4.7. Infection Control Programs	609
4.8. Fungal Infections	611
5. Phase II: Infections to Day 100	615
5.1. Interstitial Pneumonia	615
5.2. CMV-Associated Pneumonia	617
5.3. <i>Pneumocystis carinii</i> Pneumonia	619
5.4. Idiopathic Interstitial Pneumonia	620

5.5. Other Manifestations of CMV Infection	621
5.6. Herpes Simplex Virus Infection	621
5.7. Other Protozoan Infections	623
6. Phase III: After 100 Days	623
6.1. Varicella–Zoster Virus Infection	623
6.2. Late Infections in Patients with Graft-versus-Host Disease	624
7. Future Considerations	624
References	625

24 Infection in the Organ Transplant Recipient 629

ROBERT H. RUBIN

1. Introduction	629
2. Risk of Infection in the Organ Transplant Recipient	632
2.1. Epidemiologic Exposures of Importance	632
2.2. The Net State of Immunosuppression	633
3. Timetable of Infection in the Organ Transplant Recipient	634
4. Infection Occurring in the First Month Posttransplant	636
4.1. Preexisting Infection in the Allograft Recipient	636
4.2. Infection from the Donor	638
4.3. Wound Infection	640
4.4. Other Causes of Infection in the First Month	644
4.5. Noninfectious Causes of Fever in the First Month Posttransplant	645
5. Infection 1–6 Months Posttransplant	646
5.1. Herpes Group Virus Infections in the Organ Transplant Recipient	646
5.2. Hepatitis in the Organ Transplant Recipient	669
5.3. HIV Infection in the Organ Transplant Recipient	674
5.4. Papovaviruses in the Organ Transplant Recipient	675
5.5. Urinary Tract Infection in the Renal Transplant Patient	675
6. Infection in Organ Transplant Patients More Than 6 Months Posttransplant	676
7. Infectious Disease Problems of Particular Importance in the Organ Transplant Patient	677
7.1. Central Nervous System Infection in the Organ Transplant Patient	677
7.2. Bacteremia in the Organ Transplant Recipient	682
7.3. Fungal Infections in the Organ Transplant Recipient	682
7.4. Mycobacterial Infections in the Organ Transplant Patient	684
8. Principles of Antimicrobial Therapy in the Organ Transplant Recipient	685
9. Summary and Prospects for the Future	685
References	686

25 Surgical Aspects of Infection in the Compromised Host 707

A. BENEDICT COSIMI

1. Introduction	707
2. Diagnostic Approach	707
2.1. Pneumonia in the Immunocompromised Host	707
2.2. Gastrointestinal Complications of the Immunosuppressed State	708
2.3. Occult Intra-abdominal Sources of Fever and Infection	712
3. Preoperative Preparation	713
3.1. Infection and Adrenal Insufficiency	714
3.2. Infection and Ketoacidosis	714
3.3. Infection and Malnutrition	715
3.4. Preoperative Antibiotics	716
4. Intraoperative Considerations	716
4.1. Choice of Anesthesia and Patient-Monitoring Techniques	716

4.2. Surgical Technique	717
4.3. The Effect of AIDS on Surgical Practice.....	720
5. Postoperative Management	721
5.1. Respiratory Management in the Immunocompromised Patient	721
5.2. General Postoperative Care in the Immunocompromised Patient.....	722
5.3. Management of the Burn or Trauma Patient	722
5.4. Postoperative Gastrointestinal Bleeding in the Immunocompromised Patient	725
5.5. Sepsis following Splenectomy	726
6. Conclusions	727
References	727

Index	731
--------------------	------------

Clinical Approach to Infection in the Compromised Host

Third Edition